Latest Oncosil Medical News

Page 1 of 4
OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.
Victor Sage
Victor Sage
30 Oct 2026
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
OncoSil Medical has moved closer to local production after contract manufacturer Cyclotek secured ISO 13485 certification for its quality management system. Production at the Macquarie Park facility remains targeted for the end of 2Q FY27, subject to further regulatory approval.
Victor Sage
Victor Sage
9 Sept 2026
OncoSil Medical has secured $5.6 million from its three largest institutional investors to fund commercial launches of its OncoSil device in the United States and Australia. The commitments follow FDA and TGA approvals and would lift pro-forma cash to $12.1 million once completed.
Ada Torres
Ada Torres
7 Sept 2026
OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.
Ada Torres
Ada Torres
28 Aug 2026
OncoSil Medical has won FDA Humanitarian Device Exemption approval for its OncoSil™ device to treat distal cholangiocarcinoma, opening a US market estimated at A$80 million annually.
Ada Torres
Ada Torres
17 Aug 2026
OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.
Ada Torres
Ada Torres
30 July 2026
OncoSil Medical has gained Saudi FDA approval for its OncoSil™ device, enabling full reimbursement and commercial access in Saudi Arabia, the Middle East's largest healthcare market.
Ada Torres
Ada Torres
20 July 2026
OncoSil Medical has completed key manufacturing validation cycles with Cyclotek, paving the way for scalable Australian production of its OncoSil™ device. With a $2.1 million capital investment, the company aims to boost margins and supply chain control ahead of commercial launch in late 2026.
Ada Torres
Ada Torres
13 July 2026
OncoSil Medical has submitted its Humanitarian Device Exemption application to the FDA for its OncoSil™ device targeting distal cholangiocarcinoma, entering the final review phase with a decision expected within 45 days.
Ada Torres
Ada Torres
3 July 2026
OncoSil Medical secures a spot in the PALACROS consortium, advancing its OncoSil™ device through a cost-efficient Phase II trial targeting unresectable locally advanced pancreatic cancer.
Ada Torres
Ada Torres
2 July 2026
OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.
Ada Torres
Ada Torres
9 June 2026

Browse the archive

Full archive